Fordadistrogene Movaparvovec

Summary

Fordadistrogene Movaparvovec (CHEMBL4594336) is a phase-3 clinical-stage gene; indicated across 1 condition including duchenne muscular dystrophy.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Gene
• Indications: 1 condition
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594336
Name	Fordadistrogene Movaparvovec
Type	Gene
Max phase	3

Also known as: Aav9.hck.opti-dys.delta.3978, Fordadistrogene movaparvovec, PF-06939926, FORDADISTROGENE MOVAPARVOVEC

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Duchenne muscular dystrophy	3	MONDO:0010679	MONDO:0010679

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04281485	PHASE3	ACTIVE_NOT_RECRUITING	Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy
NCT05689164	PHASE3	TERMINATED	A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.
NCT05429372	PHASE2	TERMINATED	Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy
NCT03362502	PHASE1	TERMINATED	A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).